RecruitingNot ApplicableNCT04252781

Incident Chronic Obstructive pulmoNary dIsease Cohort Study (ICONIC)

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

300 participants

Start Date

Aug 20, 2020

Study Type

INTERVENTIONAL

Conditions

Chronic Obstructive Pulmonary Disease Smokers

Summary

Chronic Obstructive Pulmonary Disease (COPD), , secondary to smoking, is a major public health issue with very high direct and indirect costs. The impact on the health system of undiagnosed patients, up to 70% of patients, is increasingly documented. However, systematic spirometry screening remains controversial among smokers in the absence of data to link the detection of new patients with improved management and clinical events and health goals. More generally, there is little data on the evolution of patients in real life once they have entered the care system. The premise is that with systematic screening in general medicine, it is possible to identify the evolution of newly diagnosed COPD patients, to distinguish the different possible evolutions according to the initial phenotype and the management.

Eligibility

Min Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking heavy smokers to identify COPD (chronic obstructive pulmonary disease — a lung condition that makes it hard to breathe) in its earliest stages, before symptoms become severe, and then following patients over time to learn about how the disease progresses. **You may be eligible if:** - You are over 35 years old - You have smoked more than 20 pack-years (e.g., a pack a day for 20 years) - You are currently an active smoker (stopped less than a month ago) - You are willing to have breathing tests done **You may NOT be eligible if:** - You already have a known diagnosis of COPD - You are currently being treated for active cancer - You are pregnant or breastfeeding - You are not covered by social security or another social protection scheme Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERExhaustive exploration

* clinical investigations * imagery * blood assessment * functional respiratory investigations * muscle function / skeletal muscle index

Locations(1)

Hopital Henri MONDOR

Créteil, Île-de-France Region, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04252781

Related Trials

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222194 locations

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209183 locations

Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD

NCT050613681 location

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT066032467 locations

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769484 locations